Davids, M. S., Ostojic, A., Wargo, S., Hodari, M., Munley, J., Hermann, R. (2025). Mutation-guided finite-duration acalabrutinib plus venetoclax for relapse after first-line finite-duration COVALENT Bruton tyrosine kinase inhibitor plus venetoclax‒based combination therapy in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: Phase 2 MAVRiC study. Blood. https://doi.org/10.1182/blood-2025-3912